What are the efficacy and effects of larotinib/larlotinib? Which patients are suitable for use?

Larotrectinib is a highly selective TRK inhibitor, mainly targeting patients with solid tumors carrying NTRK gene fusion mutations. Different from traditional tumor treatment methods, this drug is unique in that it is "tissue agnostic", that is, no matter what organ the tumor occurs in, as long as NTRK fusion mutations are detected, it is likely to respond well to larotrectinib. Therefore, the drug is widely used to treat a variety of solid tumors, such as lung cancer, thyroid cancer, soft tissue sarcoma, childhood tumors (such as infantile fibrosarcoma), etc.

The main mechanism of action of larotrectinib is to target theTRK (nerve growth factor receptor tyrosine kinase) signaling pathway and block the abnormal proliferation of tumor cells caused by NTRK fusion mutations. NTRK gene fusion is a rare driver mutation with a low incidence, but once present, it is often associated with the progression of highly malignant tumors. Clinical studies have shown that larotrectinib has significant anti-tumor activity in NTRK fusion-positive patients, with an overall objective response rate (ORR) of more than 75%, and some patients can achieve complete response (CR). More importantly, regardless of the patient's age, cancer type, or whether they have received other treatments, larotrectinib can demonstrate a durable therapeutic effect and benefit many patients with advanced or relapsed disease.

The drug is usually administered orally, twice a day, and has a rapid onset of action. Some patients can observe the shrinkage of lesions within 1-2 weeks after taking the drug. Imaging examinations generally show obvious effects after 4-8 weeks. Larotrectinib is well tolerated and has relatively mild side effects, which mainly include fatigue, dizziness, nausea, anemia, abnormal liver function, etc. Most patients can tolerate it well, but in a few cases, the dose may need to be adjusted or the drug may be temporarily discontinued.

Reference link:https://www.vitrakvi.com/